Methylenedioxyallylamphetamine

This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources. Find sources: "Methylenedioxyallylamphetamine" – news · newspapers · books · scholar · JSTOR (October 2017)

Methylenedioxyallylamphetamine

Names
Preferred IUPAC name N-[1-(2H-1,3-Benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine
Identifiers
CAS Number	74698-45-6 Y
3D model (JSmol)	Interactive image
ChemSpider	21106331 N
PubChem CID	44719581
UNII	HYC85U2R8Z Y
CompTox Dashboard (EPA)	DTXSID40660369
InChI InChI=1S/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3 N Key: BMKCDDFQEGYEJC-UHFFFAOYSA-N N InChI=1/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3 Key: BMKCDDFQEGYEJC-UHFFFAOYAO
SMILES C1=C2C(=CC=C1CC(C)NCC=C)OCO2
Properties
Chemical formula	C13H17NO2
Molar mass	219.284 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

Methylenedioxyallylamphetamine (MDAL or 3,4-methylenedioxy-N-allylamphetamine) is a lesser-known psychedelic drug. It is also the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 180 mg, and the duration unknown.^[1] MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.